AAPS PharmSciTech

, Volume 15, Issue 4, pp 910–919 | Cite as

In Vitro-Controlled Release Delivery System for Hydrogen Sulfide Donor

Research Article

Abstract

Hydrogen sulfide (H2S) is having many potential pharmacological and physiological actions which reported that therapeutically useful concentration is low (100–160 μM) and a higher concentration could be toxic. Most of its donors produce it on coming into contact with water. All of these problems could be solved by a controlled-release delivery system which does not utilize water in any of its development steps. Therefore, 12 sustained release formulations were prepared by dissolving sodium hydrogen sulfide (NaHS)—a model H2S donor—in polymer solutions, prepared by dissolving polymers (consisted of either polylactide (PLA) or polylactide co-glycolide (PLGA), containing free carboxylic acid or capped allyl ester end group) in a mixture of benzyl benzoate (BB) and benzyl alcohol (BA). The formulation was injected in simulated tear fluid (STF) from which samples were withdrawn at specified times and assayed for NaHS content. We found decrease in burst and overall release with increase in polymer concentration from 10 to 20% w/v. The formulations containing free end group showed significant (p < 0.05) reduction of burst release (11% vs 21%). However, the overall release or the average amount released per hour was found to be significantly (p < 0.05) increased for formulations containing polymers with free end group than those with capped end group. A sustained level of H2S was found to be maintained for 72 h which should be further increased to a month to make it a viable H2S donor delivery system in addition to investigating toxicity profile specifically for the purpose of subconjunctival ocular delivery.

KEY WORDS

controlled release hydrogen sulfide hydrogen sulfide donor in situ gel forming phase sensitive smart polymer 

References

  1. 1.
    Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev. 2012;92:791–896.PubMedCrossRefGoogle Scholar
  2. 2.
    Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci. 1996;16:1066–71.PubMedGoogle Scholar
  3. 3.
    Doeller JE, Isbell TS, Benavides G, Koenitzer J, Patel H, Patel RP, et al. Polarographic measurement of hydrogen sulfide production and consumption by mammalian tissues. Anal Biochem. 2005;341:40–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Lowicka E, Beltowski J. Hydrogen sulfide (H2S)—the third gas of interest for pharmacologists. Pharmacol Rep. 2007;9:4–24.Google Scholar
  5. 5.
    Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007;6:917–35.PubMedCrossRefGoogle Scholar
  6. 6.
    Goodwin LR, Francom D, Dieken FP, Taylor JD, Warenycia MW, Reiffenstein RJ, et al. Determination of sulfide in brain tissue by gas dialysis/ion chromatography: postmortem studies and two case reports. J Anal Toxicol. 1989;13:105–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Warenycia MW, Goodwin LR, Benishin CG, Reiffenstein RJ, Francom DM, Taylor JD, et al. Acute hydrogen sulfide poisoning. Demonstration of selective uptake of sulfide by the brainstem by measurement of brain sulfide levels. Biochem Pharmacol. 1989;38:973–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Hu LF, Lu M, Hon Wong PT, Bian JS. Hydrogen sulfide: neurophysiology and neuropathology. Antioxid Redox Signal. 2011;15:405–19.PubMedCrossRefGoogle Scholar
  9. 9.
    Stipanuk MH, Beck PW. Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. Biochem J. 1982;206:267–77.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Erickson PF, Maxwell IH, Su LJ, Baumann M, Glode LM. Sequence of cDNA for rat cystathionine gamma-lyase and comparison of deduced amino acid sequence with related Escherichia coli enzymes. Biochem J. 1990;269:335–40.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Swaroop M, Bradley K, Ohura T, Tahara T, Roper MD, Rosenberg LE, et al. Rat cystathionine beta-synthase. Gene organization and alternative splicing. J Biol Chem. 1992;267:11455–61.PubMedGoogle Scholar
  12. 12.
    Wang R. Hydrogen sulfide: the third gasotransmitter in biology and medicine. Antioxid Redox Signal. 2010;12:1061–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Fiorucci S, Distrutti E, Cirino G, Wallace JL. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology. 2006;131:259–71.PubMedCrossRefGoogle Scholar
  14. 14.
    Gong QH, Shi XR, Hong ZY, Pan LL, Liu XH, Zhu YZ. A new hope for neurodegeneration: possible role of hydrogen sulfide. J Alzheimers Dis. 2011;2:173–82.Google Scholar
  15. 15.
    Kimura H. Hydrogen sulfide as a neuromodulator. Mol Neurobiol. 2002;26:13–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Tygi N, Moshal KS, Sen U, Vacek TP, Kumar M, Highes Jr WM, et al. H2S protects against methionine-induced oxidative stress in brain endothelial cell. Antioxid Redox Signal. 2009;11:25–33.CrossRefGoogle Scholar
  17. 17.
    Whiteman M, Cheung NS, Zhu YZ, Chu SH, Siau JL, Wong BS, et al. Hydrogen sulphide: a novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain. Biochem Byophys Res Commun. 2005;326:794–8.CrossRefGoogle Scholar
  18. 18.
    Kimura Y, Dargusch R, Schubert D, Kimura H. Hydrogen sulfide protects HT22 neuronal cells from oxidative stress. Antioxid Redox Signal. 2006;8:661–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Kimura Y, Kimura H. Hydrogen sulfide protects neurons from oxidative stress. J Fed Ame Soc Exep Bio. 2004;18:1165–7.Google Scholar
  20. 20.
    Eto K, Asad T, Arima K, Makifuchi T, Rimura H. Brain hydrogen sulfide is severely decreased in Alzheimer’s disease. Biochem Biophys Res Commun. 2002;293:1485–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Lee M, Schwab C, Yu S, McGeer E, McGeer P. Astrocytes produce the anti-inflammatory and neuroprotective agent hydrogen sulphide. Neurobiol Aging. 2009;30:1523–34.PubMedCrossRefGoogle Scholar
  22. 22.
    Liu YH, Lu M, Hu LF, Wong PT, Webb GD, Bian JS. Hydrogen sulfide in the mammalian cardiovascular system. Antioxid Redox Signal. 2012;17:141–85.PubMedCrossRefGoogle Scholar
  23. 23.
    Whiteman M, Armstrong JS, Chu SH, Siau JL, Cheung NS, Halliwell B, et al. The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite “scavenger”. J Neurochem. 2004;90:765–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Lefer DJ. A new gaseous signaling molecule emerges: cardioprotective role of hydrogen sulfide. Proc Natl Acad Sci. 2007;46:17907–8.CrossRefGoogle Scholar
  25. 25.
    Ohia SE, Opere CA, Monjok EM, Kouamou G, Leday AM, Njie-Mbye YF. Role of hydrogen sulfide production in inhibitory action of l-cysteine on isolated porcine irides. Curr Eye Res. 2010;35:402–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Njie-Mbye YF, Bongmba OY, Onyema CC, Chitnis A, Kulkarni M, Opere CA, et al. Effect of hydrogen sulfide on cyclic AMP production in isolated bovine and porcine neural retinae. Neurochem Res. 2010;35:487–94.PubMedCrossRefGoogle Scholar
  27. 27.
    Perrino E, Uliva C, Lanzi C, Soldato PD, Masini E, Sparatore A. New prostaglandin derivative for glaucoma treatment. Bioorg Med Chem Let. 2009;19:1639–42.CrossRefGoogle Scholar
  28. 28.
    Kasparek MS, Linden DR, Kreis ME, Sarr MG. Gasotransmitters in the gastrointestinal tract. Surgery. 2007;143:455–9.CrossRefGoogle Scholar
  29. 29.
    Wang R. The gasotransmitter role of hydrogen sulfide. Antiox Red Sig. 2003;5:493–501.CrossRefGoogle Scholar
  30. 30.
    Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionin gamma-lyase. Science. 2008;322:587–90.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Tayel SA, El-Nabarawi MA, Tadros MI, Abd-Elsalam WH. Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Int J Pharm. 2013;443:293–305.PubMedCrossRefGoogle Scholar
  32. 32.
    Cohen S, Lobel E, Trevgoda A, Peled Y. A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Rel. 1997;44:201–8.CrossRefGoogle Scholar
  33. 33.
    Cline JD. Spectrophotometric determination of hydrogen sulfide in natural waters. Limnol Oceanogr. 1969;14:454–8.CrossRefGoogle Scholar
  34. 34.
    Hayton WL, Chen T. Correction of perfusate concentration for sample removal. J Pharm Sci. 1982;71:820–1.PubMedCrossRefGoogle Scholar
  35. 35.
    Craig JP, McNeill R, Tomlinson A. Comparison of salinity and osmolality of human tears, poster# 50 (VB-303). Optom Vis Sci. 1995;72:133–4.CrossRefGoogle Scholar
  36. 36.
    Hägerström H, Paulsson M, Edsman K. Evaluation of mucoadhesion for two polyelectrolyte gels in simulated physiological conditions using a rheological method. Eur J Pharm Sci. 2000;9:301–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Carroll JJ, Mather AE. The solubility of hydrogen sulphide in water from 0 to 90°C and pressures to 1 MPa. Geochim Cosmochim Acta. 1989;53:1163–70.CrossRefGoogle Scholar
  38. 38.
    Kirsten WJ. On the ethylene blue reaction and its use for determination of sulphide. Mikrochim Acta. 1978;11:403–9.CrossRefGoogle Scholar
  39. 39.
    Lindsay SS, Baedecker MJ. Determination of aqueous sulfide in contaminated and natural water using the methylene blue method. Ground-water contamination : field methods : a symposium / sponsored by ASTM committees D-19 on Water and D-18 on Soil and Rock, Cocoa Beach, FL, 1986; 349–57.Google Scholar
  40. 40.
    Martelli A, Testai L, Breschi MC, Blandizzi C, Virdis A, Taddei S, et al. Hydrogen sulphide: novel opportunity for drug discovery. Med Res Rev. 2012;32:1093–130.PubMedCrossRefGoogle Scholar
  41. 41.
    Hughes MN, Centelles MN, Moore KP. Making and working with hydrogen sulfide: the chemistry and generation of hydrogen sulfide in vitro and its measurement in vivo: a review. Free Radic Bio Med. 2009;47:1346–53.CrossRefGoogle Scholar
  42. 42.
  43. 43.
    Chaubal MV, Kipp J, Rabinow B. Excipient selection and criteria for injectable dosage forms. In: Katdare A, Chaubal MV, editors. Excipient development for pharmaceutical, biotechnology, and drug delivery systems. New York: CRC Press; 2006. p. 271–90.CrossRefGoogle Scholar
  44. 44.
    Merck Index, 13th Ed., Merck & Co., Inc., Whitehouse, NJ, 2001; 1132.Google Scholar
  45. 45.
    Al-Tahami K, Singh J. Smart polymer based delivery systems for peptides and proteins. Rec Pat Drug Del Form. 2007;1:65–71.CrossRefGoogle Scholar
  46. 46.
    Ohia SE, Opere CA, Zhan G, Monjok E, Kulkami K, Kouamou GE. Use of hydrogen sulfide in the treatment of eye diseases. 2012;US Patents 8092838.Google Scholar
  47. 47.
    Chitkara D, Shikanov A, Kumar N, Domb AJ. Biodegradable injectable in situ depot‐forming drug delivery systems. Macromol Biosci. 2006;6:977–90.PubMedCrossRefGoogle Scholar
  48. 48.
    Chhabra S, Sachdeva V, Singh S. Influence of end groups on in vitro release and biological activity of lysozyme from a phase-sensitive smart polymer-based in situ gel forming controlled release drug delivery system. Int J Pharm. 2007;342:72–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Graham P, Brodbeck K, McHugh A. Phase inversion dynamics of PLGA solutions related to drug delivery. J Control Rel. 1999;58:233–45.CrossRefGoogle Scholar
  50. 50.
    Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci. 1961;50:874–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67:217–23.PubMedGoogle Scholar
  52. 52.
    Wang L, Venkatraman S, Kleiner L. Drug release from injectable depots: two different in vitro mechanisms. J Control Rel. 2004;99:207–16.CrossRefGoogle Scholar
  53. 53.
    Chen S, Singh J. Controlled delivery of testosterone from smart polymer solution based systems: in vitro evaluation. Int J Pharm. 2005;295:183–90.PubMedCrossRefGoogle Scholar
  54. 54.
    Testa M, Iuliano G, Morton P, Longoni A. Topical benzyl alcohol reduces cataract surgery need: two long-term double blind studies. J Ocul Pharmacol. 1987;3(3):211–25.PubMedCrossRefGoogle Scholar
  55. 55.
    Grant WM, Schuman JS. Toxicology of the eye: effects on the eyes and visual system from chemicals, drugs, metals and minerals, plants, toxins, and venoms; also, systemic side effects from eye medications. 4th ed. Springfield: Thomas; 1993. p. 575.Google Scholar
  56. 56.
    Massmann W. Toxicological investigations on dimethylformamide. Br J Ind Med. 1956;13(1):51–4.PubMedCentralPubMedGoogle Scholar
  57. 57.
    Hanna C, Fraunfelder FT, Meyer SM. Effects of dimethyl sulfoxide on ocular inflammation. Ann Ophthalmol. 1977;9(1):61–5.PubMedGoogle Scholar
  58. 58.
    Kaufman PL, Erickson KA. Cytochalasin B and D dose-outflow facility response relationships in the cynomolgus monkey. Invest Ophthalmol Vis Sci. 1982;23(5):646–50.PubMedGoogle Scholar
  59. 59.
    Bourges JL, Gautier SE, Delie F, Bejjani RA, Jeanny JC, Gurny R, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003;44(8):3562–9.PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2014

Authors and Affiliations

  1. 1.Teva PharmaceuticalsPomonaUSA
  2. 2.Department of Pharmacy Sciences, School of Pharmacy and Health ProfessionsCreighton UniversityOmahaUSA

Personalised recommendations